Data Code Sets
To receive email updates about this page, enter your email address:
For more information on background and concepts see Understanding the Rules for Creating CVX and MVX Codes [5 pages]
More ways to access CDC’s Vaccine Code Set information: Code Set Viewpoint search/browse website and REST Web Service
Fall Season Respiratory Vaccine Codes
The current Fall vaccine code and crosswalk tables for COVID-19, RSV, and Influenza are provided in the following summary tables.
Fall 2023 COVID-19 Vaccine Codes and Crosswalks
The following table provides a preview and summary of the vaccine codes and crosswalks that will be activated if the FDA authorizes use and ACIP votes to recommend the candidate vaccines.
Note: Codes in the following table are effective and published in the full vaccine code sets only upon EUA issuance or BLA licensure of COVID-19 vaccine(s) by the Food and Drug Administration (FDA). Additional code details and fields values are included in the vaccine code sets once published.
Download the Fall 2023 COVID-19 Vaccine Code Crosswalk table
| Manufacturer (MVX) | Product Label Tradename (*) | CVX Code | CVX Term Description | CVX Short Description | NDC Virus Strain | UoS NDC10 UoS NDC11 |
Packaging | UoU NDC10 UoU NDC11 |
Age Cohort; Presentation |
CPT Code | CPT Description |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer (PFR) |
COMIRNATY (COVID-19 Vaccine, mRNA, 2023-2024 Formula) | 309 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 30 mcg/0.3 mL dose | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL | SARS-CoV-2 virus strain Omicron XBB.1.5 | 0069-2362-10 00069-2362-10 |
CARTON, 10 SINGLE-DOSE VIALS | 0069-2362-01 00069-2362-01 |
Ages 12 years and older; VIAL, SINGLE-DOSE, 30 mcg/0.3 mL |
91320 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
| Pfizer (PFR) |
COMIRNATY (COVID-19 Vaccine, mRNA, 2023-2024 Formula) | 309 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 30 mcg/0.3 mL dose | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL | SARS-CoV-2 virus strain Omicron XBB.1.5 | 0069-2392-10 00069-2392-10 |
CARTON, 10 PRE-FILLED SYRINGES | 0069-2392-01 00069-2392-01 |
Ages 12 years and older; SYRINGE, PRE-FILLED, 30 mcg/0.3 mL |
91320 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
| Pfizer (PFR) |
Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) | 310 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 10 mcg/0.3 mL dose | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL | SARS-CoV-2 virus strain Omicron XBB.1.5 | 59267-4331-2 59267-4331-02 |
CARTON, 10 SINGLE-DOSE VIALS | 59267-4331-1 59267-4331-01 |
Ages 5 through 11 years; VIAL, SINGLE-DOSE, 10 mcg/0.3 mL |
91319 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
| Pfizer (PFR) |
Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) | 308 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 3 mcg/0.3 mL dose | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL | SARS-CoV-2 virus strain Omicron XBB.1.5 | 59267-4315-2 59267-4315-02 |
CARTON, 10 MULTI-DOSE VIALS | 59267-4315-1 59267-4315-01 |
Ages 6 months through 4 years; VIAL, MULTI-DOSE, 3 DOSES, 3mcg / 0.3 mL AFTER DILUTION |
91318 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
| Novavax (NVX) |
Novavax COVID-19 Vaccine, Adjuvanted | 313 | SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 5 mcg/0.5 mL dose | COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL | SARS-CoV-2 virus strain Omicron XBB.1.5 | 80631-105-02 80631-0105-02 |
CARTON, 2 MULTI-DOSE VIALS | 80631-105-01 80631-0105-01 |
Ages 12 years and older; VIAL, MULTI-DOSE, 5 DOSES, 5 mcg/0.5 mL |
91304 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use |
| Moderna (MOD) |
Spikevax | 312 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | SARS-CoV-2 virus strain Omicron XBB.1.5 | 80777-102-95 80777-0102-95 |
CARTON, 10 SINGLE-DOSE VIALS | 80777-102-04 80777-0102-04 |
Ages 12 years and older; VIAL, SINGLE-DOSE, 50 mcg/0.5 mL |
91322 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use |
| Moderna (MOD) |
Spikevax | 312 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | SARS-CoV-2 virus strain Omicron XBB.1.5 | 80777-102-96 80777-0102-96 |
CARTON, 10 PRE-FILLED SYRINGES | 80777-102-01 80777-0102-01 |
Ages 12 years and older; SYRINGE, PRE-FILLED, 50 mcg/0.5 mL |
91322 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use |
| Moderna (MOD) |
Spikevax | 312 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | SARS-CoV-2 virus strain Omicron XBB.1.5 | 80777-102-93 80777-0102-93 |
CARTON, 10 BLISTER-SEALED PRE-FILLED SYRINGES | 80777-102-01 80777-0102-01 |
Ages 12 years and older; SYRINGE, PRE-FILLED, 50 mcg/0.5 mL |
91322 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use |
| Moderna (MOD) |
Moderna COVID-19 Vaccine | 311 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 25 mcg/0.25 mL dose | COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL | SARS-CoV-2 virus strain Omicron XBB.1.5 | 80777-287-92 80777-0287-92 |
CARTON, 10 SINGLE-DOSE VIALS | 80777-287-07 80777-0287-07 |
Ages 6 months through 11 years; VIAL, SINGLE-DOSE, 25 mcg/0.25 mL |
91321 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use |
(*) Product Label Tradename: If the manufacturer name is included in the tradename, the vaccine product is to be provided under Emergency Use Authorization (EUA), once FDA EUA issuance is received. Other tradenames are for vaccine products to be provided under BLA licensure, once approved.
Other COVID-19 Vaccine Related Codes and Links
Information regarding currently active EUA Recipient and Caregiver Fact Sheet URLs and Codes can be found here.
Registered users can access COVID-19 vaccine lot numbers and expiration dates provided to CDC by the vaccine manufacturer.
Information regarding Previous COVID-19 pandemic Emergency Use Authorization (EUA) and BLA codes and crosswalks can be found here.
Respiratory Syncytial Virus (RSV) Codes and Crosswalks
The following table includes the RSV codes and crosswalks included in the CDC IIS Vaccine Code Sets. Note that the CPT codes shown are not mapped to the NDC codes, but are mapped to the CVX codes shown. CPT codes provided in the vaccine code sets are to assist with code categorizations and are not intended to represent billable codes.
Download the RSV Crosswalk table
| CVX Code | CVX Description | Sale Proprietary Name | Sale Labeler | MVX Code | Unit of Sale NDC11 | Unit of Use NDC11 | Presentation | CPT Code | CPT Description |
|---|---|---|---|---|---|---|---|---|---|
| 303 | Respiratory syncytial virus (RSV), vaccine, recombinant, protein subunit RSV prefusion F, adjuvant reconstituted, 0.5 mL, preservative free | Arexvy | GlaxoSmithKline Biologicals SA | SKB | 58160-848-11 | 58160-723-03 | VIAL, 0.5 mL, reconstituted | 90679 | Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use |
| 305 | Respiratory syncytial virus (RSV), vaccine, bivalent, protein subunit RSV prefusion F, diluent reconstituted, 0.5 mL, preservative free | Abrysvo | Pfizer Laboratories Div Pfizer Inc | PFR | 0069-0344-01 0069-0344-05 0069-0344-10 |
0069-0207-01 | VIAL, 0.5 mL, reconstituted | 90678 | Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use |
| CVX Code | CVX Description | Sale Proprietary Name | Sale Labeler | MVX Code | Unit of Sale NDC11 | Unit of Use NDC11 | Presentation | CPT Code | CPT Description |
|---|---|---|---|---|---|---|---|---|---|
| 306 | Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 0.5 mL, neonates and children to 24 months | BEYFORTUS | Sanofi Pasteur Inc. | PMC | 49281-575-15 | 49281-575-00 | SYRINGE, 0.5 mL | 90380 | Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use |
| 307 | Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 1 mL, neonates and children to 24 months | BEYFORTUS | Sanofi Pasteur Inc. | PMC | 49281-574-15 | 49281-574-88 | SYRINGE, 1 mL | 90381 | Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use |
(*) The BEYFORTUS nirsevimab monoclonal antibody codes are included in the vaccine code set in a manner similar to regular vaccines to enable reporting or other program data exchange in accordance with ACIP and CDC guidelines.
| CVX Code | CVX Description | CVX Note |
|---|---|---|
| 314 | Respiratory syncytial virus (RSV) vaccine, unspecified | Unspecified, for historic records where the specific vaccine administered is not known |
| 315 | Respiratory syncytial virus (RSV) monoclonal antibody (MAB), unspecified | Unspecified, for historic records where the specific RSV MAB administered is not known |
| 304 | Respiratory syncytial virus (RSV), unspecified | Unspecified, for historic records where it is not known if RSV vaccine or RSV MAB was administered |
Guidance relating to RSV vaccines can be found at Home page for MMWR | MMWR (cdc.gov)
On July 17, 2023, the Food and Drug Administration licensed Nirsevimab (Beyfortus), a long-acting monoclonal antibody for the prevention of respiratory syncytial virus (RSV) in infants and young children. It is anticipated that the Advisory Committee on Immunization Practices (ACIP) will vote on potential recommendations for use of this product and its inclusion in the Vaccines for Children (VFC) program at the August 3rd ACIP meeting.
New codes listed above have been added in anticipation of potential recommendations. More information to support integration into VFC, as well as details around vaccine codes, Clinical Decision Support for Immunization (CDSi), and any data collection requirements will be published as they become available.
2023/2024 Seasonal Influenza Codes and Crosswalk
This new format includes all seasonal influenza vaccines for the 2023/2024 season in a single Excel crosswalk table that provides the CVX, MVX, NDC Unit of Sale, NDC Unit of Use, and CPT (*) codes for each vaccine.
(*) Please note that the CPT codes shown for each vaccine crosswalk are not mapped to the NDC codes, but are mapped to the CVX codes shown. These are reference CPT codes for vaccine categorization and are not intended to represent billable codes.
| CVX Code | CVX Short Description | Sale Proprietary Name | Sale Labeler | MVX Code | Unit of Sale NDC11 | Unit of Use NDC11 | Presentation | CPT Code | CPT Description |
|---|---|---|---|---|---|---|---|---|---|
| 149 | influenza, live, intranasal, quadrivalent | FluMist Quadrivalent | MedImmune, LLC | MED | 66019-0310-10 | 66019-0310-01 | APPLICATOR 0.2 mL | 90672 | Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use |
| 150 | Influenza, injectable, quadrivalent, preservative free | Afluria Quadrivalent | Seqirus PTY LTD. | SEQ | 33332-0323-03 | 33332-0323-04 | SYRINGE, 0.5 mL | 90686 | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use |
| 150 | influenza, injectable, quadrivalent, preservative free | FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | SKB | 58160-0909-52 | 58160-0909-41 | SYRINGE, 0.5 mL | 90686 | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use |
| 150 | influenza, injectable, quadrivalent, preservative free | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | IDB | 19515-0814-52 | 19515-0814-41 | SYRINGE, 0.5 mL | 90686 | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use |
| 150 | influenza, injectable, quadrivalent, preservative free | Fluzone Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | PMC | 49281-0423-50 | 49281-0423-88 | SYRINGE, 0.5 mL | 90686 | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use |
| 158 | influenza, injectable, quadrivalent, contains preservative | Afluria Quadrivalent | Seqirus PTY LTD. | SEQ | 33332-0423-10 | 33332-0423-11 | VIAL, 5 mL, MULTI-DOSE | 90687 | Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use |
| 90688 | Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | ||||||||
| 158 | influenza, injectable, quadrivalent | Fluzone Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | PMC | 49281-0639-15 | 49281-0639-78 | VIAL, 5 mL, MULTI-DOSE | 90687 | Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use |
| 90688 | Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | ||||||||
| 171 | Influenza, injectable, MDCK, preservative free, quadrivalent | Flucelvax Quadrivalent | Seqirus Inc. | SEQ | 70461-0323-03 | 70461-0323-04 | SYRINGE, 0.5 mL | 90674 | Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use |
| 185 | influenza, recombinant, quadrivalent,injectable, preservative free | Flublok Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | PMC | 49281-0723-10 | 49281-0723-88 | SYRINGE, 0.5 mL | 90682 | Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use |
| 186 | Influenza, injectable, MDCK, quadrivalent, preservative | Flucelvax Quadrivalent | Seqirus Inc. | SEQ | 70461-0423-10 | 70461-0423-11 | VIAL, 5 mL, MULTI-DOSE | 90756 | Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use |
| 197 | influenza, high-dose, quadrivalent | Fluzone High-Dose Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | PMC | 49281-0123-65 | 49281-0123-88 | SYRINGE, 0.7 mL | 90662 | Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use |
| 205 | Influenza vaccine, quadrivalent, adjuvanted | FLUAD QUADRIVALENT | Seqirus, Inc. | SEQ | 70461-0123-03 | 70461-0123-04 | SYRINGE, 0.5 ml | 90694 | Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use |
| CVX Code | CVX Short Description | Sale Proprietary Name | Sale Labeler | MVX Code | Unit of Sale NDC11 | Unit of Use NDC11 | Presentation | CPT Code | CPT Description |
|---|---|---|---|---|---|---|---|---|---|
| 200 | influenza, Southern Hemisphere, pediatric, preservative free | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | PMC | NA | NA | SYRINGE, 0.25 mL | NA | NA |
| 201 | influenza, Southern Hemisphere, preservative free | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | PMC | 49281-0323-50 | 49281-0323-88 | SYRINGE, 0.5 mL | NA | NA |
| 202 | influenza, Southern Hemisphere, quadrivalent, with preservative | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | PMC | 49281-0355-15 | 49281-0355-78 | VIAL, MULTI-DOSE, 5 mL | NA | NA |
| 231 | influenza, Southern Hemisphere, high-dose, quadrivalent | FLUZONE High-Dose Quadrivalent Southern Hemisphere | Sanofi Pasteur Inc. | PMC | 49281-0379-50 | 49281-0379-88 | SYRINGE, .7 mL | NA | NA |